inclusion criteria: * diagnosis of covid-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours prior to informed consent * males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy * females must have a negative pregnancy test at screening * participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol

inclusion criteria: * diagnosis of covid-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours prior to informed consent * males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication * females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy * females must have a negative pregnancy test at screening * participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol

inclusion criteria: - diagnosis of covid-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours prior to informed consent - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol

inclusion criteria: - diagnosis of covid-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with fda-cleared molecular diagnostic assay positive for sars-cov-2 within 72 hours prior to informed consent - males must be sterile, or agree not to donate semen and agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must be unable to bear children, or ensure that their male partner is incapable of fathering a child, or, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication - females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy - females must have a negative pregnancy test at screening - participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol